Evidence map›Paper›PMID 27352929›Full record

ArticleStem cells translational medicine2016

Enforced Expression of HOXB4 in Human Embryonic Stem Cells Enhances the Production of Hematopoietic Progenitors but Has No Effect on the Maturation of Red Blood Cells.

Melany Jackson, Rui Ma, A Helen Taylor, Richard A Axton, Jennifer Easterbrook, Maria Kydonaki, Emmanuel Olivier, Lamin Marenah, Edouard G Stanley, Andrew G Elefanty and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. A human iPSC line capable of differentiating into functional macrophages expressing ZsGreen: a tool for the study andPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Melany JacksonCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Rui MaCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
A Helen TaylorCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Richard A AxtonCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Jennifer EasterbrookCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Maria KydonakiCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Emmanuel OlivierInstitute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom Scottish National Blood Transfusion Service, Edinburgh, United Kingdom.
Lamin MarenahInstitute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom Scottish National Blood Transfusion Service, Edinburgh, United Kingdom.
Edouard G StanleyMurdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Andrew G ElefantyMurdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia Department of Anatomy and Developmental Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Joanne C MountfordInstitute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom Scottish National Blood Transfusion Service, Edinburgh, United Kingdom.
Lesley M ForresterCentre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom L.Forrester@ed.ac.uk.
University of Edinburgh · GBBritish Heart Foundation · GBMRC Centre for Regenerative Medicine · GBMurdoch Children's Research Institute · AUUniversity of Glasgow · GBUniversity of Melbourne · AU

Funding

Medical Research Council MR/K017047/1Medical Research Council MR/L012766/1Wellcome Trust
6 · The paper itself

Abstract

unlabelled: We have developed a robust, Good Manufacturing Practice-compatible differentiation protocol capable of producing scalable quantities of red blood cells (RBCs) from human pluripotent stem cells (hPSCs). However, translation of this protocol to the clinic has been compromised because the RBCs produced are not fully mature; thus, they express embryonic and fetal, rather than adult globins, and they do not enucleate efficiently. Based on previous studies, we predicted that activation of exogenous HOXB4 would increase the production of hematopoietic progenitor cells (HPCs) from hPSCs and hypothesized that it might also promote the production of more mature, definitive RBCs. Using a tamoxifen-inducible HOXB4-ER(T2) expression system, we first demonstrated that activation of HOXB4 does increase the production of HPCs from hPSCs as determined by colony-forming unit culture activity and the presence of CD43(+)CD34(+) progenitors. Activation of HOXB4 caused a modest, but significant, increase in the proportion of immature CD235a(+)/CD71(+) erythroid cells. However, this did not result in a significant increase in more mature CD235a(+)/CD71(-) cells. RBCs produced in the presence of enhanced HOXB4 activity expressed embryonic (ε) and fetal (γ) but not adult (β) globins, and the proportion of enucleated cells was comparable to that of the control cultures. We conclude that programming with the transcription factor HOXB4 increases the production of hematopoietic progenitors and immature erythroid cells but does not resolve the inherent challenges associated with the production of mature adult-like enucleated RBCs. SIGNIFICANCE: As worldwide blood donations decrease and transfusable transmitted infections increase, intense interest has ensued in deriving red blood cells (RBCs) in vitro from alternative sources such as pluripotent stem cells. A translatable protocol was developed to generate RBCs; however, these RBCs have an immature phenotype. It was hypothesized that the transcription factor HOXB4 could enhance their production and maturation. Although HOXB4 increased the production of erythroid progenitors, it did not promote their maturation. Despite the remaining challenges, a robust system has been established to test other candidates and add to the knowledge base in this field.

Indexed as

Cell DifferentiationCell LineageBiomarkersCell ProliferationCells, CulturedCellular ReprogrammingCellular Reprogramming TechniquesEmbryonic Stem CellsErythrocytesGene Expression Regulation, DevelopmentalHematopoietic Stem CellsHomeodomain ProteinsHumansPhenotypeTime FactorsTranscription FactorsBiomarkersHomeodomain ProteinsHOXB4 protein, humanTranscription FactorsCD34+Cell surface markersColony formationDifferentiationElectroporationEmbryonic stem cellsErythroid differentiationTranscription factor

Identifiers

PMID27352929
PMCPMC4954454
OpenAlexW2466499783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.